MAZE

8-K - Maze Therapeutics, Inc. (0001842295) (Filer)

424B5 - Maze Therapeutics, Inc. (0001842295) (Filer)

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions a

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

3 - Maze Therapeutics, Inc. (0001842295) (Issuer)

10-K - Maze Therapeutics, Inc. (0001842295) (Filer)

8-K - Maze Therapeutics, Inc. (0001842295) (Filer)

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028 SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceu

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated – – The subgroup of AMKD patients with FSGS that were treated with MZE829 showed a 61.8% mean reduction in uACR – – Treatment of non-diabetic AMKD patients with MZE829 led to a clinically meaningful mean reduction in uACR from baseline of 48.6% – – Results provide first clinical proof-of-concept in genetically defined, broad AMKD population, including patients with moderate proteinuria and diabetes – – Maze plans to advance MZE829 to a pivotal program – – Maze to host investor conference c

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

Truist initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $68.00

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

Mizuho initiated coverage of Maze Therapeutics with a rating of Outperform and set a new price target of $97.00

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 a.m. ET. A live webcast of the event will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentation. About Maze Therapeutics Maze Therapeutics is a clinical-stage biopharmaceutical co

SCHEDULE 13G/A - Maze Therapeutics, Inc. (0001842295) (Subject)

S-8 - Maze Therapeutics, Inc. (0001842295) (Filer)

S-3ASR - Maze Therapeutics, Inc. (0001842295) (Filer)

8-K - Maze Therapeutics, Inc. (0001842295) (Filer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)